Drug Trial Radar · NCT07023315
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
760
Planned (sponsor's estimate)
Start
Aug 14, 2025
Primary completion
Jul 2029
Study completion Jul 2031
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Jun 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer.
Conditions
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions
CadonilimabDrug
Anti-PD-1/ CTLA-4 tetrameric bispecific antibody
SOX chemotherapyDrug
A combination treatment made up of oxaliplatin and tegafur-gimeracil-oteracil potassium
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS)Time frame: Up to 5 years
- Pathological Complete Response (pathCR) RateTime frame: Up to approximately 2 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Tianjin Provincial Tumor Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.